The Effect of Extract of Green Tea on Obese Women and Obese Related Hormone Peptides
The Effect of Extract of Green Tea on Obese Women Obese Related Hormone Peptides
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Taipei, Taiwan
- Taipei City Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- aged between 20 and 60 years old women
- Chinese
- body mass index (BMI) > 27 kg/m2
- waist circumference (WC) > 80 cm
- willing to participate in and fill out the questionnaires for this trial.
Exclusion Criteria:
- GPT > 80 U/L, serum creatinine > 2.0 mg/dl
- breast feeding or pregnancy
- heart failure
- acute myocardial infarction
- Stroke
- any other conditions not suitable for trial as evaluated by the physician
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: EGCG(Epigallocatechin Gallate)
EGCG(Epigallocatechin Gallate)(500 mg, three times a day, 12 weeks)
|
500mg, three times a day, duration:12 weeks
Other Names:
|
|
Placebo Comparator: placebo
cellulose (500mg, three times a day, 12 weeks)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
composite of anthropometric measures
Time Frame: compare between the beginning of the study and after 12 weeks of treatment.
|
composite include body weight, waist circumference, hip circumference
|
compare between the beginning of the study and after 12 weeks of treatment.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Hormone peptide change
Time Frame: compared between the beginning of the study and after 12 weeks of treatment
|
hormone peptides such as leptin、adiponectin、ghrelin、fasting insulin resistance、APOB、APOA1
|
compared between the beginning of the study and after 12 weeks of treatment
|
|
biochemical characteristic change
Time Frame: compare between the beginning of the study and after 12 weeks of treatment.
|
blood sugar, creatinine, aminotransferases aspartate, aminotransferases alanine, uric acid and
|
compare between the beginning of the study and after 12 weeks of treatment.
|
|
traditional chinese medicine syndrome classification
Time Frame: compare between the beginning of the study and after 12 weeks of treatment.
|
Use questionaire to classify traditional chinese medicine syndrome in obese women
|
compare between the beginning of the study and after 12 weeks of treatment.
|
|
Quality of life evaluation
Time Frame: compare between the beginning of the study and after 12 weeks of treatment.
|
(1)12-item Short-Form Health Survey (2)WHOQoL-BREF
|
compare between the beginning of the study and after 12 weeks of treatment.
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: Chung-Hua Hsu, PHD, Taipei medical hospital, Linsen Chinese Medicine branch
Publications and helpful links
General Publications
- Hsu CH, Tsai TH, Kao YH, Hwang KC, Tseng TY, Chou P. Effect of green tea extract on obese women: a randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2008 Jun;27(3):363-70. doi: 10.1016/j.clnu.2008.03.007. Epub 2008 May 12.
- Chen IJ, Liu CY, Chiu JP, Hsu CH. Therapeutic effect of high-dose green tea extract on weight reduction: A randomized, double-blind, placebo-controlled clinical trial. Clin Nutr. 2016 Jun;35(3):592-9. doi: 10.1016/j.clnu.2015.05.003. Epub 2015 May 29.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Lipid Metabolism Disorders
- Dyslipidemias
- Diabetes Mellitus
- Hyperlipidemias
- Hyperlipoproteinemias
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Neuroprotective Agents
- Protective Agents
- Antioxidants
- Anticarcinogenic Agents
- Antimutagenic Agents
- Epigallocatechin gallate
Other Study ID Numbers
Other Study ID Numbers
- 100XDAA00110 (Other Grant/Funding Number: 100XDAA00110)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.